Oral Lesions Following Anti-SARS-CoV-2 Vaccination: A Systematic Review

Federica Di Spirito (), Alessandra Amato, Maria Pia Di Palo, Maria Contaldo, Francesco D’Ambrosio, Roberto Lo Giudice and Massimo Amato
Additional contact information
Federica Di Spirito: Department of Medicine, Surgery and Dentistry, University of Salerno, 84084 Salerno, Italy
Alessandra Amato: Department of Neuroscience, Reproductive Science and Dentistry, University of Naples Federico II, 80138 Naples, Italy
Maria Pia Di Palo: Department of Medicine, Surgery and Dentistry, University of Salerno, 84084 Salerno, Italy
Maria Contaldo: Multidisciplinary Department of Medical-Surgical and Odontostomatological Specialities, University of Campania “Luigi Vanvitelli”, 81100 Naples, Italy
Francesco D’Ambrosio: Department of Medicine, Surgery and Dentistry, University of Salerno, 84084 Salerno, Italy
Roberto Lo Giudice: Department of Human Pathology in Adulthood and Childhood “G. Barresi”, University Hospital “G. Martino” of Messina, Via Consolare Valeria 1, 98123 Messina, Italy
Massimo Amato: Department of Medicine, Surgery and Dentistry, University of Salerno, 84084 Salerno, Italy

IJERPH, 2022, vol. 19, issue 16, 1-18

Abstract: Increasing evidence relate anti-SARS-CoV-2 vaccinations to orofacial adverse reactions, therefore, the present systematic review aimed to evaluate primary oral lesions diagnosed in adult subjects, following the WHO Emergency Use Listing approved and EMA authorized vaccines, also in relation to cases’ age, gender, comorbidities, and history of COVID-19, and in relation to vaccine type and doses. The study protocol, registered on PROSPERO (CRD42022339032) and compliant with the PRISMA statement, included an electronic search across Scopus, MEDLINE/PubMed, BioMed Central databases, and PROSPERO, ended on 18 June 2022 and succeeded by a manual search, an independent data extraction, and arisk of bias evaluation through ROBINS-I tool. Qualitatively synthesized data from the 13studies included showed an overall low prevalence (16 cases), though higher in females (68.8%), of oral lesions, mainly erosions and ulcers (34.5%). Nine cases were diagnosed following Pfizer-BioNTech, two Moderna, and one AstraZeneca, Serum Institute of India, Sinopharm, and Johnson&Johnson vaccines, respectively; specifically, eight after the first dose and seven after the second. In one case, vaccine type and dose were not specified. Considering newly developing vaccines, presented findings may be updated and further studies needed to highlight factors affecting oral lesion occurrence and specific macro-microscopic phenotypes in relation to cases’ and vaccines’ characteristics.

Keywords: SARS-CoV-2; coronavirus disease 2019; COVID-19; oral lesions; vaccine; vaccination (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (3)

Downloads: (external link)
https://www.mdpi.com/1660-4601/19/16/10228/pdf (application/pdf)
https://www.mdpi.com/1660-4601/19/16/10228/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:19:y:2022:i:16:p:10228-:d:890772

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().